Literature DB >> 35018340

COVID-19 with a heavily mutated variant in a multiple myeloma after vaccination: Correspondence.

Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Year:  2022        PMID: 35018340      PMCID: PMC8736279          DOI: 10.1016/j.clinpr.2021.100132

Source DB:  PubMed          Journal:  Clin Infect Pract        ISSN: 2590-1702


× No keyword cloud information.
Dear Editor, we would like to share ideas on the publication “Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination (Stampfer et al., 2022).” Stampfer et al. noted that “Multiple myeloma patients who do develop detectable antibody responses to vaccination may be ……… in viral passaging experiments, likely require a higher level of anti-spike antibodies to prevent severe COVID-19. (Stampfer et al., 2022).” We agree that this patient with underlying myeloma had COVID-19 infection. Regardless of having multiple myeloma or not, any vaccinated person is at risk of becoming infected with a mutated variant. The efficacy of vaccines against variants of COVID-19 is still undergoing evaluation. Additionally, the effectiveness of standard two dose of COVID-19 vaccine among patients with underlying malignancy or other immunosuppression might be less than healthy people. The need for further vaccine boosters is being investigated and encouraged in many countries (Pappas et al., 2021).

Authors contributions

RM 50 % - 1a Substantial contributions to study conception and design 1b. Substantial contributions to acquisition of data 1c. Substantial contributions to analysis and interpretation of data 2. Drafting the article or revising it critically for important intellectual content 3. Final approval of the version of the article to be published VW 50 % - 1a Substantial contributions to study conception and design 1b. Substantial contributions to acquisition of data 1c. Substantial contributions to analysis and interpretation of data 2. Drafting the article or revising it critically for important intellectual content 3. Final approval of the version of the article to be published

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  2 in total

1.  Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination.

Authors:  Samuel D Stampfer; Marissa-Skye Goldwater; Sean Bujarski; Bernard Regidor; Wenjuan Zhang; Aaron J Feinstein; Regina Swift; Shahrooz Eshaghian; Eric Vail; James R Berenson
Journal:  Clin Infect Pract       Date:  2021-12-09

Review 2.  Vaccine third dose and cancer patients: necessity or luxury?

Authors:  G Pappas; E Saloustros; A Boutis; N Tsoukalas; M Nikolaou; A Christopoulou; S Agelaki; I Boukovinas; A Ardavanis; Z Saridaki
Journal:  ESMO Open       Date:  2021-11-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.